Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$25.22 +1.3%	$21.19	$15.47 ▼ $36.37	$851.55M	1.26	207,165 shs	441,501 shs
CTMX CytomX Therapeutics	$2.32 +10.0%	$1.74	$0.40 ▼ $3.10	$170.11M	2.11	2.19 million shs	8.05 million shs
IMNM Immunome	$8.75 -0.9%	$8.49	$5.15 ▼ $16.81	$768.32M	1.94	917,847 shs	1.32 million shs
PHAR Pharming Group	$10.60 -2.3%	$9.93	$6.65 ▼ $12.61	$737.82M	0.02	6,101 shs	1,340 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+1.33%	+8.38%	+23.20%	+29.20%	+44.03%
CTMX CytomX Therapeutics	+9.95%	-15.64%	+13.73%	+247.93%	+79.84%
IMNM Immunome	-0.91%	-4.89%	+10.48%	+6.97%	-34.11%
PHAR Pharming Group	-5.27%	-2.49%	+1.05%	+19.05%	+24.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.3834 of 5 stars	3.6	0.0	0.0	2.6	0.8	0.0
CTMX CytomX Therapeutics	3.724 of 5 stars	3.5	1.0	4.7	0.0	1.7	1.3
IMNM Immunome	1.6143 of 5 stars	3.5	0.0	0.0	2.2	2.5	0.0
PHAR Pharming Group	2.4558 of 5 stars	3.5	3.0	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	55.77% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	129.89% Upside
IMNM Immunome	3.00	Buy	$23.33	166.67% Upside
PHAR Pharming Group	3.00	Buy	$30.00	183.02% Upside

Current Analyst Ratings Breakdown

Latest CTMX, AVBP, IMNM, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/2/2025	IMNM Immunome	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
CTMX CytomX Therapeutics	$138.10M	1.35	$0.40 per share	5.83	($0.01) per share	-232.00
IMNM Immunome	$9.04M	84.22	N/A	N/A	$2.27 per share	3.85
PHAR Pharming Group	$297.20M	2.43	$0.07 per share	146.30	$3.25 per share	3.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	4.83	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	353.33	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)

Latest CTMX, AVBP, IMNM, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
CTMX CytomX Therapeutics	N/A	1.73	1.73
IMNM Immunome	N/A	10.49	10.49
PHAR Pharming Group	0.39	2.76	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CTMX CytomX Therapeutics	67.77%
IMNM Immunome	44.58%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
CTMX CytomX Therapeutics	6.60%
IMNM Immunome	8.60%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
IMNM Immunome	40	87.01 million	79.53 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable

CTMX, AVBP, IMNM, and PHAR Headlines

Recent News About These Companies

Pharming Group (NASDAQ:PHAR) Shares Down 3.2% - Here's Why

June 18 at 2:18 PM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's What Happened

June 17, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?

June 16, 2025 | marketbeat.com

Short Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%

June 13, 2025 | marketbeat.com

European Penny Stocks Under €200M Market Cap To Watch

June 13, 2025 | uk.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What Happened

June 12, 2025 | marketbeat.com

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

June 11, 2025 | finance.yahoo.com

Pharming Group Announces Key Board Appointments and Approvals at 2025 AGM

June 11, 2025 | tipranks.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's Why

June 11, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What Happened

June 10, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Stock Price Up 6.7% - Here's What Happened

June 6, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

June 5, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What Happened

June 4, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Reaches New 1-Year High - What's Next?

June 3, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Large Decline in Short Interest

June 3, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What Happened

May 31, 2025 | marketbeat.com

Pharming Group to participate in June investor conferences

May 28, 2025 | finance.yahoo.com

Pharming Group to participate in June investor conferences | PHARM Stock News

May 28, 2025 | gurufocus.com

Pharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

May 10, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q1 - Results - Earnings Call Presentation

May 9, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, AVBP, IMNM, and PHAR Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$25.22 +0.33 (+1.33%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$25.25 +0.03 (+0.12%)

As of 06/20/2025 07:59 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

CytomX Therapeutics NASDAQ:CTMX

$2.32 +0.21 (+9.95%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.35 +0.03 (+1.08%)

As of 06/20/2025 07:38 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$8.75 -0.08 (-0.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$8.74 -0.02 (-0.17%)

As of 06/20/2025 04:55 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Pharming Group NASDAQ:PHAR

$10.60 -0.25 (-2.30%)

Closing price 06/20/2025 03:58 PM Eastern

Extended Trading

$10.60 0.00 (0.00%)

As of 06/20/2025 05:16 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time